RE:RE:RE:RE:RE:RE:General question for the board
Glad you brought that valid point up...
CG0070 requires treatments spanning almost 2 years, & there's an expanded cohort (US & Japan) that would receive maintenance treatments for up to 3 years...it's kind of like getting endless booster shots in order to keep the immune system triggered/awake. The fact that so many doses are required in this protocol, my guess is that once you stop dosing, immunity will wane thereby increasing risk of recurrence. Additionally, such extended treatments impose an intense burden on patients, docs & the overall healthcare system, which makes this endless treatment course expensive & less practical for many.
As you suggested, the more interesting/telling data will be the durable response rate "after" all treatments have been stopped. The "pseudo-CR" will then show its true colors. It's also somewhat a "pseudo-comparison" when one compares two different classes of drugs, which is the case when comparing our ACT with CGON's.
People need to understand that just because a drug may be best in/across-class, doesn't mean it's the best option for patients & the healthcare system.
The FDA clearly understands this when considering the nature of this unmet disease & FDA's prior approvals. JMO..